An overview of some potential immunotherapeutic options against COVID-19

Bayat, Maryam; Asemani, Yahya; Mohammadi, Mohammad Reza; Sanaei, Mahsa; Namvarpour, Mozhdeh; Eftekhari, Reyhaneh

doi:10.1016/j.intimp.2021.107516

Cited by 9 publications

(6 citation statements)

References 223 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is widely accepted that cytokine storm significantly increases ICU stay, the need for mechanical ventilation, and increased mortality in COVID‐19. 28 , 29 Abnormal immune‐inflammatory response causes hyper‐activation of CD4 and CD8 lymphocytes, which subsequently causes tissue necrosis, and fibrosis in visceral organs. 30 Autopsy of pulmonary tissue and CT scan findings have revealed bilateral diffuse alveolar damage and fibroblastic multiplication in alveolar tissues.…”

Section: Discussionmentioning

confidence: 99%

“…Inefficacy of a wide spectrum of antiviral drugs against SARS‐CoV‐2 has questioned their use in COVID‐19, and concurrently there are a number of large cohort studies that report hyper‐inflammation and immune dysfunction named as cytokine storm as pathogenic hotspots in severe progression in COVID‐19. It is widely accepted that cytokine storm significantly increases ICU stay, the need for mechanical ventilation, and increased mortality in COVID‐19 28,29 . Abnormal immune‐inflammatory response causes hyper‐activation of CD4 and CD8 lymphocytes, which subsequently causes tissue necrosis, and fibrosis in visceral organs 30 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Repurposing of Mycobacterium indicus pranii for the severe form of COVID‐19 patients in India: A cohort study

Shah

Dar

Quibtiya

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces the production of proinflammatory cytokines, which results in a cytokine storm, and immune‐modulators like Mycobacterium indicus pranii (MIP) might ameliorate coronavirus disease of 2019 (COVID‐19) related cytokine storm. Therefore, the present study evaluates whether MIP offers an advantage in the treatment of severe COVID‐19 patients infected with SARS‐CoV‐2. A prospective MIP cohort study was conducted in chest disease hospitals in Srinagar, Jammu and Kashmir, India. In the present prospective, randomized clinical study, critically severe COVID‐19 patients were divided into two groups, the MIP group (n = 105) and the best standard treatment (BST) group (n = 210). Procalcitonin, ferritin, high‐sensitive C‐reactive protein, D‐dimer levels, and interleukin levels on 5th‐day posttreatment were significantly reduced in the MIP group compared to the BST group. Compared to the BST group, 105 consecutive patients with severe COVID‐19 in the MIP group reported early weaning off ventilation, resolution of chest architecture (computed tomography [CT] scan), a significant increase in SpO2 levels, and decreased mortality with a hazard ratio: 0.234 (95% confidence interval: 0.264–2.31) (p = 0.001). MIP restored SpO2, immune/inflammatory response, normalized lung abnormalities (chest CT scan), and reduced mortality without any serious complications. However, there is a need for placebo‐controlled double‐blind and controlled clinical trials to confirm the efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Repurposing of Mycobacterium indicus pranii for the severe form of COVID‐19 patients in India: A cohort study

Shah

Dar

Quibtiya

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Although progress with the application of vaccines and other therapeutic measures is being made, the COVID-19 widespread pandemic continues to spread all across the globe, with high mortality rates and especially in high-risk patients, which currently constitutes a major public health concern ( Artese et al, 2020 ; Bayat et al, 2021 ; Twomey et al, 2020 ). The new drug discovery process has been difficult due to very little knowledge about the molecular mechanism involved in SARS-CoV-2 infection ( De et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab′)2 fragment derived from equine polyclonal antibodies

Salinas

Marelli

Sanguineti³

et al. 2022

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

“…À medida que a biodisponibilidade de NAMPT aumenta, o receptor Toll-like 4, que é responsável pela inflamação pulmonar é ativado. Dessa forma, a neutralização do NAMPT circulante por anticorpos monoclonais pode ser outra abordagem viável na prevenção da lesão pulmonar causada por Covid-19 (Bayat et al, 2021).…”

Section: Neutralizadores Do Namptunclassified

Terapia da Covid-19 com anticorpos monoclonais

Silva¹,

Felício²,

Oliveira³

et al. 2022

RSD

View full text Add to dashboard Cite

Em dezembro de 2019, na cidade de Wuhan, surgiu uma nova variante viral causadora de um surto de síndrome respiratória de origem desconhecida. Em paralelo a isto, foram desenvolvidas várias vacinas eficazes como também estão em andamento estudos de candidatos a fármacos capazes de limitar e prevenir a replicação do vírus. Esta revisão objetiva investigar na literatura científica o uso de possíveis estratégias de tratamento de anticorpos monoclonais contra infecção por SARS-CoV-2. Foi realizada uma revisão sistemática na literatura disponível nas bases de dados PubMed, Scielo e ScienceDirect, utilizando como descritores: Covid-19, Monoclonal Antibodies e Immunotherapy publicados nos idiomas português, inglês e espanhol, com intervalo de 2020 a 2022. Dos 638 estudos encontrados, 17 foram selecionados. As terapias de anticorpos monoclonais neutralizantes direcionadas ao SARS-CoV-2 foram consideradas terapias potenciais promissoras para o Covid-19, pertencentes a distintas classes farmacológicas tais como os inibidores da proteína spike, inibidores da IL-6, inibidores da IL-1-β, inibidores do ACE2, neutralizadores do NAMP, anti-fator estimulador de granulócitos-macrófagos, anti-CD6 IgG1 porém sua produção em larga escala para aplicação clínica é trabalhosa, cara e custosa. Dessa forma, é notável os avanços dos tratamentos imunoterapeuticos mas também se faz necessário a projeção e desenvolvimento de plataformas avançadas de produção de proteínas afim de fornecer anticorpos monoclonais eficientes a um custo acessível em um curto espaço de tempo.

show abstract

An overview of some potential immunotherapeutic options against COVID-19

Cited by 9 publications

References 223 publications

Repurposing of Mycobacterium indicus pranii for the severe form of COVID‐19 patients in India: A cohort study

Repurposing of Mycobacterium indicus pranii for the severe form of COVID‐19 patients in India: A cohort study

Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab′)2 fragment derived from equine polyclonal antibodies

Terapia da Covid-19 com anticorpos monoclonais

Contact Info

Product

Resources

About